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The majority of individuals who become acutely infected with hepatitis C virus (HCV)
develop chronic infection and suffer from progressive liver damage while approximately
25% are able to eliminate the virus spontaneously. Despite the recent introduction of new
direct-acting antivirals, there is still no vaccine for HCV. As a result, new infections and rein-
fections will remain a problem in developing countries and among high risk populations
like injection drug users who have limited access to treatment and who continue to be
exposed to the virus. The outcome of acute HCV is determined by the interplay between
the host genetics, the virus, and the virus-specific immune response. Studies in humans
and chimpanzees have demonstrated the essential role of HCV-specific CD4 and CD8 T
cell responses in protection against viral persistence. Recent data suggest that antibody
responses play a more important role than what was previously thought. Individuals who
spontaneously resolve acute HCV infection develop long-lived memoryT cells and are less
likely to become persistently infected upon reexposure. New studies examining high risk
cohorts are identifying correlates of protection during real life exposures and reinfections.
In this review, we discuss correlates of protective immunity during acute HCV and upon
reexposure. We draw parallels between HCV and the current knowledge about protective
memory in other models of chronic viral infections. Finally, we discuss some of the yet
unresolved questions about key correlates of protection and their relevance for vaccine
development against HCV.
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INTRODUCTION
Hepatitis C virus (HCV), a member of the family Flaviviridae, is a
non-cytopathic hepatotropic virus transmitted primarily through
contaminated blood (1). The World Health Organization (WHO)
estimates that there are 185 million individuals infected with HCV
worldwide (2, 3). The prevalence is higher in developing countries,
the highest being in Egypt where it is estimated that 15–20% are
seropositive for HCV (4, 5). These numbers are probably an under-
estimate, since many HCV-infected individuals have not been
tested and thus remain undiagnosed.
The acute phase of hepatitis C is empirically defined as the first
6 months following infection. Approximately, 20–30% of infected
individuals are able to clear the virus spontaneously without any
therapeutic intervention during this phase while 70–80% become
persistently infected (1). As the virus continues to replicate in the
liver of chronically infected individuals, they develop a variety of
liver diseases over a period of 5–30 years including hepatic fibro-
sis, end-stage cirrhosis, and hepatocellular carcinoma (HCC) (6).
Such patients represent 25% of the cirrhosis and HCC cases world-
wide (7), making hepatitis C the most common indication for liver
transplantation in North America (8, 9).
Despite the progress in understanding immunity against HCV
infection and its pathogenesis and, the development of highly
effective direct-acting antivirals (DAAs), a prophylactic anti-HCV
vaccine is still lacking. In absence of such a vaccine, two mil-
lion new HCV infections are estimated to occur every year (10).
Such cases are highly prevalent among marginalized populations
like injection drug users (IDUs), men who have sex with men
(MSM), and individuals living in developing countries with lim-
ited access to screening and treatment (11, 12). Vaccine develop-
ment against HCV is hampered by our limited knowledge of what
constitutes an effective and protective immune response against
HCV, as well as protection in real life exposure settings. Many
shades of gray remain and constitute active areas of the current
research on hepatitis C. In the following pages, we will attempt to
review the correlates of protection against HCV and identify these
outstanding questions and the ongoing efforts to address them.
THE VIRUS
The HCV genome consists of an uncapped positive single-
stranded RNA (+ssRNA) of approximately 9.6 kb-pairs (13). The
genome represents an uninterrupted open reading frame (ORF)
encoding a polyprotein precursor of approximately 3000 amino
acids (13). The viral genome includes 5′ and 3′ untranslated
regions (UTRs) that contain secondary RNA structures essential
for viral replication. The 5′ UTR harbors an internal ribosome
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entry site (IRES) where protein translation is initiated. The HCV
polyprotein is processed co- and post-translationally by a combi-
nation of cellular and viral proteases into three structural proteins
(Core, E1, and E2) and seven non-structural (NS) proteins (P7,
NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Figure 1). Core is the
building unit of the viral nucleocapsid. The envelope glycoproteins
E1 and E2 interact with the viral receptors on permissive cells and
mediate viral entry. E2 also contains hypervariable regions (HVR)
that are targeted by neutralizing antibodies (nAbs). P7 acts as a
viroporin or ion channel. NS2 possesses an autoprotease activity
necessary for the polyprotein cleavage between NS2 and NS3. NS3
acts as serine protease in combination with NS4A that acts as a
cofactor to catalyze the processing of the HCV polyprotein. NS3
also harbors RNA helicase/NTPase activity that unwinds RNA–
RNA substrates and is essential for viral replication [reviewed in
Ref. (14, 15)]. The functions of NS4B and NS5A are poorly char-
acterized. However, studies show that NS4B induces the formation
of a membranous web compartment where viral replication takes
place (16), and cell-culture adaptive mutations mapped to the
NS5A enhance RNA replication suggesting its importance for viral
replication (17, 18). NS5A was also shown to harbor a region
that may determine response to alpha interferon (IFN-α) ther-
apy known as interferon sensitivity determining region (ISDR)
(19). NS5B is the viral RNA-dependent RNA-polymerase (RdRp)
responsible for HCV–RNA replication (14). As with other RNA
viruses, the HCV RdRp enzyme lacks proof-reading activity and
is highly error prone, leading to the emergence of different viral
populations circulating in the blood of an individual patient as a
mosaic of highly related sequences termed “quasispecies” (14).
Hepatitis C virus is classified into seven genotypes (1–7) and
up to 67 different subtypes based on the nucleotide sequences
of the Core/E1 and NS5B regions (20). The different genotypes
show marked differences in geographic distribution, response to
therapy, and pathogenesis (15).
VIRAL REPLICATION AND LIFE CYCLE
Hepatitis C virus replicates primarily in human hepatocytes. The
first described receptors for HCV were CD81 (21) and scav-
enger receptor class B type I (SR-BI) (22). The LDL receptor and
glycosaminoglycans (GAG) mediate initial binding to suscepti-
ble cells prior to interaction with CD81 and SR-BI (15). Tight
junction proteins claudin-1 (CLDN1) and occludin (OCLN) act
as receptors/co-receptors for HCV at cell junctions (23, 24). It
was recently reported that the cholesterol absorption receptor
Niemann–Pick C1-like 1 (NPC1L1) is an essential entry factor
(25) and that the epidermal growth factor receptor (EGFR) and
ephrin receptor type A2 are also required for HCV entry and pos-
sibly modulate the interaction between CD81 and CLDN1 (26).
Human CD81 and OCLN are the minimally required receptors to
render mouse hepatocytes susceptible to HCV entry (24). Binding
of HCV to its receptors is followed by fusion of the viral enve-
lope with the cellular membrane by clathrin-mediated endocytosis
then fusion with the endosomal membrane and the viral genome
is released into the cytosol (27). Cap-independent IRES-mediated
translation of the HCV ORF generates a large polyprotein that is
subsequently processed into mature structural and NS proteins
(Figure 1). Junctions between structural proteins are processed by
host signal peptidases from the endoplasmic reticulum. The viral
NS proteins are processed by the NS2/3 autoprotease (14) and the
NS3/4A serine protease (28). Replication takes place within ER
derived structures known as the membranous web and is mediated
by NS5B through a negative strand intermediate in a replica-
tion complex. Viral assembly occurs within lipid raft like struc-
tures. HCV nucleocapsid is built from units of the core protein
with RNA, surrounded by a membrane derived from the human
cell with embedded heterodimers of the envelope glycoproteins
E1 and E2 [reviewed in Ref. (15)]. The virions associate with
low-density and very-low-density lipoproteins (LDL and VLDL)
forming lipoviroparticles (LVPs) that are pleomorphic (29).
FIGURE 1 | HCV genome and polyprotein.The HCV genome is
composed of an open reading frame (ORF) flanked by 5’ and 3’
untranslated regions (UTRs). IRES-mediated translation of the ORF leads
to the formation of a polyprotein that is processed into 10 viral proteins.
Cleavage of the core protein from E1 involves cellular signal peptidases,
which also cleave E1, E2, and p7 from the polyprotein (pink arrows). The
NS2–NS3 protease auto-cleaves itself (green arrow). The NS3 protease
located in the first one-third of NS3, assisted by its membrane-bound
cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A,
and NS5B (violet arrows).
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MODELS FOR STUDYING HCV INFECTION AND IMMUNITY
IN VITRO MODELS
Hepatitis C virus replicates poorly in tissue culture. Earlier surro-
gate models to study HCV protein functions, virus–host interac-
tion, and viral entry included vaccinia virus (VV) vectors express-
ing HCV proteins, direct transfection of HCV RNA, subgenomic,
and full length replicons and viral pseudoparticles carrying HCV
envelop glycoproteins on a capsid backbone of vesicular stom-
atitis virus or lentiviruses (HCVpp). It was not until 2005 that
the first in vitro replicating strain was isolated from a Japanese
patient with fulminant hepatitis termed JFH-1 virus, a genotype
2a isolate (30–32). Even with the development of this system, very
few cell lines are permissive for its replication, often involving
adaptive mutations within the viral genome and/or impairment
in some of the cellular antiviral mechanisms [reviewed in Ref. (15,
33)]. These models have been instrumental in studying the innate
antiviral response against HCV on a cellular level and identifica-
tion of many of the underlying viral evasion mechanisms. The
development of new cell lines or methods that allow HCV replica-
tion in primary human or mouse hepatocytes is an area of intense
research.
IN VIVO MODELS
Humans and chimpanzees are the only two species that are sus-
ceptible to HCV infection. The chimpanzee model has been
instrumental in the early studies of immunity against HCV where
timing of the infection and infecting viral strains were known
and it was possible to examine intrahepatic immune responses.
Research on chimpanzees is now restricted (34) and the search
for an alternate animal model is ongoing. Although considerable
progress has occurred in developing humanized mice susceptible
to HCV infection, these mice are generated on immune deficient
backgrounds that preclude studying adaptive immune responses.
Cotransplantation of human CD34+ human hematopoietic stem
cells and hepatocyte progenitors in mice with inducible liver dam-
age demonstrated good engraftment of human leukocytes and
hepatocytes. These mice became infected with HCV and demon-
strated some HCV-specific immune responses and liver fibrosis
(35). These data are preliminary and the model remains techni-
cally challenging. It will likely be a few more years before we have
a suitable alternative to the chimpanzee model for studying HCV-
specific immunity and preclinical testing of vaccine candidates
[reviewed in Ref. (36)].
Due to the asymptomatic nature of HCV, a limited number of
individuals present to the clinic with acute symptomatic infection.
In that situation, it is usually difficult to determine the exact date of
infection or exposure and the infecting viral strain(s). Most of our
early knowledge about acute HCV came from studies of experi-
mental infection of chimpanzees, or individuals infected following
high risk exposures like needle stick injuries in health care workers,
blood transfusions, as well as the few cases presenting with symp-
tomatic acute HCV. Recent studies relied upon monitoring high
risk individuals, in particular IDUs who currently represent the
main population of novel HCV infection in developed countries.
It is noteworthy that in these situations the definition of acute
HCV can vary from one cohort to another and is dependent on
the follow-up interval, where the date of infection is estimated at
best. It is also ethically impossible to obtain liver biopsies during
acute infection and our knowledge of acute intrahepatic responses
is derived from the chimpanzee model.
CLINICAL COURSE OF HCV INFECTION
Hepatitis C virus RNA can be detected in the peripheral blood of
infected individuals within one week following infection. Despite
this high level of viral replication, HCV-specific immune responses
remain undetectable in most infected individuals for several weeks
suggesting that the virus outpaces the immune system and impairs
its responses (37). Nevertheless, interferon stimulated genes (ISGs)
are detected early in the liver and some mediators of innate
immunity like natural killer (NK) cells are activated and can
be detected in peripheral blood (discussed below). At approxi-
mately 4–8 weeks, HCV-specific CD4 and CD8 T cells become
detectable in the liver and peripheral blood and are often but not
always associated with an increase in liver transaminases in the
blood (38, 39). Most individuals who are able to spontaneously
clear HCV do so within the first 6 months and a smaller pro-
portion may clear their infection within 12 months. The outcome
of HCV infection is determined by a “ménage-à-trois” between
host genetics, the virus and HCV-specific immunity. Other host
factors that influence the outcome of infection include ethnicity,
female sex, and accompanying co-morbidities (e.g., co-infection
with human immunodeficiency virus (HIV), alcohol abuse, renal
disease, obesity, or liver fibrosis) (40).
GENETIC FACTORS THAT INFLUENCE THE OUTCOME OF
ACUTE PRIMARY HCV
Several genetic factors, mostly in genes related to innate and adap-
tive immune functions, influence the outcome of acute HCV infec-
tion. Individuals homozygous for the killer inhibitory receptor
(KIR) gene KIR2DL3 and its ligand HLA-C1 alleles are more likely
to clear HCV infection than individuals with other KIR2DL:HLA-
C combinations (41). KIRs interact with their cognate MHC class
I ligands and regulate the activation and function of NK cells.
KIR2DL3 has a lower affinity for HLA-C1 than other KIR2DL
alleles, so HLA-C1-mediated inhibition of NK cells is thought to
be weaker in individuals homozygous for KIR2DL3 and HLA-
C1 thus enhancing their capacity to inhibit HCV replication or
kill virally infected hepatocytes (42). The same KIR/HLA-C com-
bination was consistently more frequent in IDUs with high risk
exposure to HCV who remain seronegative/aviremic as compared
to those with chronic infection (43).
Genome-wide association studies (GWAS) demonstrated a cor-
relation between several single-nucleotide polymorphisms (SNPs)
near the IL28B (IFNλ3) gene locus and the spontaneous reso-
lution of infection, as well as response to IFN therapy (44–47).
Although several SNPs were identified, the rs12979860 SNP has
become the most relevant (48). The favorable allele was iden-
tified as CC and the non-favorable allele CT or TT for het-
erozygous or homozygous individuals, respectively. These alleles
were found to be unequally distributed among individuals of dif-
ferent ethnicities (Asians, Caucasians, and African Americans)
and correlated with their differential response to IFN therapy
(44, 47). Recent data have reported a novel transiently induced
region that carries a dinucleotide variant ss469415590 (TT or
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∆G), which is in high linkage disequilibrium with rs12979860.
This resulted in a frameshift variant that created a novel gene,
designated IFNL4, encoding the interferon-λ4 protein (49). This
mutation was also associated with higher levels of induction of
IL28B and interferon gamma-induced protein 10 (IP-10) thus
providing a potential mechanism for its enhanced role in viral
clearance (50).
It is not yet clear how polymorphism in the IL28B and/or IFNL4
gene influences immune responses and the capacity to sponta-
neously eliminate HCV. Given that the IL28B and IL29 (IFNλ1)
genes are in opposite orientation, this SNP is up stream of the
two genes and may influence expression of both. The responder
genotype was linked to higher expression of the IL28A/B as mea-
sured by qRT-PCR in PBMCs or protein levels in plasma and
lower HCV viral load, but results were not consistent among dif-
ferent studies (45, 51, 52). IL-29 was upregulated during acute
and chronic HCV and its expression correlated with induction
of ISGs but not acute infection outcome (52, 53). The non-
favorable IL28B genotype was associated with higher expres-
sion of ISGs in the liver (54–56), considered a predictor of
non-response to IFN therapy. Interestingly, ISGs were differ-
entially expressed in liver versus macrophages, where the non-
responder genotype was associated with lower ISG expression in
macrophages (56).
It was also suggested that IL28B polymorphism may influence
NK cell function or the cross-talk between innate and adaptive
immunity. Dring et al. have demonstrated that KIR2DS3 syn-
ergizes with IL28B to predict chronic evolution of HCV (57).
Suppiah et al. have demonstrated that polymorphism in IL28B,
HLA-C, and KIRs additively and interactively predict response to
therapy in chronic HCV infection (58). However, functional data
supporting this possibility are still lacking.
A more recent GWAS study demonstrated that in addition
to IL28B, another SNP near the gene for the HLA class II mol-
ecule DQB1*03:01, was independently associated with sponta-
neous resolution of HCV infection (59). Indeed, several HLA
HLA class I and class II alleles were previously associated with
the outcome of HCV [reviewed in Ref. (60)]. The HLA class
I alleles HLA-A*03, HLA-B*27, and HLA*B57 were associated
with spontaneous clearance [reviewed in Ref. (60)]. Interest-
ingly, the HLA-B*27 and -B*57 alleles are also associated with
better viral control in HIV infected individuals (61). The HLA
class II alleles HLA-DRβ1*0101, -DRB1*0401, -DRB1*1101, and
DQB1*0301 were strongly associated with HCV clearance,whereas
HLA-DRβ1*0701 was associated with HCV persistence (62–64). It
is suggested that such HLA class I and II alleles favor the generation
of immune responses targeting conserved epitopes or epitopes that
are less likely to mutate because of the high fitness cost associated
with such mutations and viral replication (65).
Other genetic factors that were associated with spontaneous
clearance of HCV include: ISGs, toll-like receptors (TLRs),
chemokines, cytokines, and their receptors [reviewed in Ref. (60)],
as well as tapasin associated with peptide loading on MHC class I
(66). Finally, HCV was also shown to exploit “holes” in the T cell
repertoire to facilitate its escape from detection by virus-specific
CD8 T cells (67).
INNATE IMMUNE RESPONSES DURING ACUTE PRIMARY
HCV
VIRAL SENSING AND INTRACELLULAR INNATE IMMUNITY
Foreign RNA molecules are recognized by pattern recognition
receptors (PRRs) including TLRs and/or intracellular nucleic acid-
binding proteins (68, 69). In hepatocytes, TLR3, protein-kinase R
(PKR), and retinoic-acid-inducible gene I (RIG-I) are the main
PRRs recognizing HCV upon entry and replication. PKR and
RIG-I activation signals are relayed via the mitochondrial antiviral
signaling protein (MAVS), while TLR3 signals are relayed via the
TIR domain-containing adapter inducing IFN-β (TRIF) [reviewed
in Ref. (70)]. Downstream of these adaptor proteins signaling cas-
cades are activated culminating in the secretion of type I IFNs
(70). Binding of auto- and paracrine type I IFNs to their receptors
activates signaling along the JAK–STAT signaling pathway. This
induces the expression of hundreds of ISGs in the infected cells
and neighboring cells (71) and creates a general antiviral state in
the liver that limits HCV RNA replication and cell-to-cell spread
(72). ISGs expressed in response to HCV infection include several
proteins with known antiviral effects, as well as some others that
were shown to promote HCV replication in vitro, as ISG15 and
USP18 (73, 74).
Upregulation of ISGs is detected in the liver early after HCV
infection irrespective of the outcome, suggesting that most HCV
isolates are resistant to the antiviral effects of this early innate
response (75–78). Nevertheless, the pro- and anti-viral roles of
the different ISGs would suggest differential induction of specific
ISGs in patients with different outcomes of HCV infection. Recent
work on primary hepatocytes infected with HCV demonstrated
that type III IFNs (IFNλs) could be the earliest responders and
that they lead to induction of ISGs shared with type I IFNs, as
well as other distinct ISGs (79, 80). Preliminary studies suggest
that although similar ISGs are induced by type I and type III IFNs,
they may signal through two distinct pathways (81), have differ-
ent kinetics (82) maybe cell type specific (56) and/or IFNλ allele
dependent (83).
Infected hepatocytes are not the only source of type I and type
III IFNs but liver resident Kupffer cells (84), BDCA3+ myeloid
dendritic cells (mDCs) (85), and plasmacytoid DCs (pDCs) (86,
87) can detect HCV RNA and produce type I and type III IFNs,
thus contributing to the intrahepatic antiviral state and inducing
inflammatory cytokines and chemokines like IP-10 that recruit
virus-specific T cells to the liver.
Despite the rapid viral sensing and induction of antiviral
responses, HCV is able to persist as it has devised several mech-
anisms to evade recognition and inhibit IFN-signaling pathways.
NS3/4A was shown to use its serine protease activity to act as the
viral “Swiss army knife” to disrupt viral sensing pathways at early
steps by splicing MAVS and TRIF downstream of the major sen-
sors of HCV–RNA [reviewed in Ref. (70)]. Other HCV proteins as
core, E2, and NS5A interfere with various early and late steps along
the JAK–STAT signaling pathway that is induced by type I and III
IFNs further contributing to inhibiting the IFN response (88–90).
However, ISGs remain highly expressed in individuals who develop
chronic infection and their level of expression correlates inversely
with the response to IFN based therapies (91). This suggests that
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sustained viral replication and induction of ISGs induce a state of
tolerance within hepatocytes that become refractory to external
IFN stimulation.
NATURAL KILLER CELLS
Natural killer cells are one of the earliest lines of innate immune
defense. They exert their function by killing virally infected cells
via secretion of cytotoxic molecules like granzymes and perforin or
through tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL)-mediated killing. They also secrete cytokines that
can regulate innate and adaptive immunity like IFNγ, TNFα, IL-
10, and IL-21. NK activity is governed by the balance between
activating and inhibitory signals. One of the major determinants
of such activity is the strength of the interaction between the
inhibitory KIRs expressed on NK cells and their MHC class I lig-
ands expressed on target cells (92). NK cells are highly enriched
in the liver and are expected to play a major role in controlling
hepatotropic infections (93, 94). NK cells were activated early in
healthcare workers following accidental percutaneous exposure
to HCV and may have contributed to protection from infection
in 11/12 individuals in this group who remained aviremic (95).
NK cells were also activated in high risk IDUs and expression of
the NK cells activating receptor NKp30 correlated with protec-
tion from HCV infection (96). Hyperactivation of NK cells was
observed during acute HCV infection irrespective of the outcome
(97–99). Increased IFNγ production was enriched in KIR2DL3
expressing NK cells as suggested by genetic studies demonstrating
that this allele was associated with spontaneous resolution of HCV
potentially due to less NK cell inhibition (98). Reduced expres-
sion of NKp30 could predict the outcome of acute HCV (97).
Notably, NK cells from HCV acutely infected individuals and dur-
ing chronic infection were biased toward cytotoxicity rather than
cytokine production (99, 100) and NK cell degranulation, a sur-
rogate marker of cytotoxicity, correlated with the magnitude of
HCV-specific T cells (99). This suggests that NK cell cytotoxic
activity may kill infected hepatocytes and facilitate the transfer of
HCV antigens to the draining lymph nodes as they are picked up
and presented by DCs.
During chronic HCV infection, intrahepatic NK cells are gener-
ally highly activated and this activation correlates with the degree
of liver inflammation (101, 102). Peripheral NK cells express vari-
able levels of the NK activation markers NKp30, NKp44, NKp46,
NKG2C, and NKG2D and increased expression of the inhibitory
receptor NKG2A as compared to healthy individuals [reviewed
in Ref. (103–105)]. NK cell numbers and functions, especially
cytotoxic activity, were shown to be lower in chronic hepati-
tis C patients as compared to healthy donors but results varied
from one study to another probably reflecting various experimen-
tal designs and patient cohorts (106–109). Recombinant HCV
E2 protein was reported to directly bind CD81 on the surface
of NK cells and inhibit its functions (110, 111). HCV-infected
hepatocyte cell lines but not purified virions reproduced a similar
phenomenon (112, 113).
Recent data from the lymphocytic choriomeningitis virus
(LCMV) model has demonstrated that NK cells may act as rheo-
stat to control CD4-mediated help for CD8 T cell functions during
chronic infection (114). Similarly, in the hepatitis B virus (HBV)
model, it was shown that NK cells can selectively eliminate acti-
vated T cells expressing the TNF-related apoptosis-inducing ligand
death receptor 2 (TRAIL-R2) and thus, negatively regulate antivi-
ral immunity (115). NK cells also interact with DCs and this
cognate interaction regulates both innate and adaptive immu-
nity. NK cells produce IFNγ and TNFα that induce maturation
of DCs and enhance their capacity to prime virus-specific T cells.
In return, DCs produce IL-12 and IL-15 that enhance activation of
NK cells (116). It would be interesting to examine if such cross talk
exists during acute HCV infection and cross-regulates adaptive
immunity.
DENDRITIC CELLS
Dendritic cells are one of the major antigen-presenting cells
(APCs) in the body. They bridge innate and adaptive immu-
nity and may impact priming of HCV-specific immune responses.
DCs rapidly differentiate into mature DCs in response to vari-
ous “danger” signals like activation through pathogen associated
molecular patterns (PAMPs) in particular TLR ligands, interac-
tion with innate lymphocytes (NK and NKT cells), cytokines, and
inflammatory mediators (117). There are two main subsets of DCs,
mDCs representing the majority of DCs and mostly associated
with antigen processing and presentation and pDCs that can sense
viral infections and are the main producers of type I and type
III IFNs. pDCs can detect HCV RNA in a TLR-7 specific manner
when presented as part of an infected cell (86). This activation can
be mediated by transfer of exosomes containing HCV–RNA from
infected cells to pDCs (87). As such, DCs are considered a main
orchestrator of the HCV innate and adaptive immune response.
The role and function of DCs during acute and chronic HCV
infection remain highly controversial. The frequencies of mDCs
and pDCs were shown to correlate with the outcome of infection,
where reduced frequencies were associated with chronic infection
(118–121). Our group has recently demonstrated that sustained
hyperresponsiveness of DCs was associated with resolution of
HCV infection suggesting better priming of HCV-specific T cells
(122). Various groups have reported that DCs are defective in
chronic HCV, in particular, in response to TLR ligands (123–126),
may be infected (123–126), and may induce proliferation of Tregs
(127) while others have demonstrated that they are functional
(118, 120, 128, 129). How do DCs influence priming of HCV-
specific immune responses? Is it through a direct effect on antigen
presentation or through better NK–DC interaction? Are DCs pre-
senting HCV antigens more tolerogenic or targets for elimination
by NK cells? These remain as some of the gray areas in the HCV
field.
ADAPTIVE IMMUNE RESPONSES DURING ACUTE PRIMARY
HCV
The importance of cell-mediated immunity in HCV clearance is
demonstrated by the correlation between specific HLA class I and
class II alleles and spontaneous resolution and underscored by
depletion studies in the chimpanzee model showing that both
CD4 and CD8 T cells are required for viral clearance and that
they have complementary rather than exclusive roles. The role of
nAbs is slowly being unraveled. In the following sections, we will
summarize the current state of knowledge on this topic.
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ONSET OF ADAPTIVE IMMUNE RESPONSES
HCV-specific CD8 and CD4 T cell responses appear late around
6–8 weeks following primary HCV infection despite high levels of
viral replication. This delay in the onset of virus-specific T cells
could be attributed to the tolerogenic nature of the liver environ-
ment and the time required for viral antigens to reach the draining
lymph nodes to be presented by professional APCs (38, 94). It
might also be indicative of the capacity of the virus to evade the
innate immune system, interfere with maturation of DCs or impair
their capacity for antigen processing and presentation. Onset of
HCV-specific CD8 T cells in blood and/or liver and the detection
of IFNγ, CD3, CD4, and CD8 transcripts in the liver are kinetically
linked to decline in viral loads (76, 77).
CD8 T CELL RESPONSES DURING ACUTE PRIMARY HCV
The breadth of the CD8 T cell response is a key determinant of
spontaneous resolution. Up to nine different epitopes were rec-
ognized simultaneously in chimpanzees and humans with acute
resolving HCV while much fewer epitopes were recognized in
individuals developing chronic infection (130, 131). Responses
targeting the NS proteins were immunodominant and correlated
with spontaneous clearance (132), but the individual epitopes tar-
geted were different, even among individuals with shared HLA
alleles (133, 134).
Escape mutations within targeted CD8 T cell epitopes are
associated with viral persistence and represent a major immune
evasion mechanism used by the virus. They typically occur early
and become fixed in the viral quasispecies (135–137). Mutated epi-
topes are mostly associated with loss of binding to the restricting
MHC and are thus not recognized or poorly induce a new T cell
response (135, 136). Escape mutations are also dependent on the
interplay between the virus and host genetics. The host HLA alleles
enforce selective pressure on their cognate epitopes. This is evident
as these mutations revert to their wild type sequences when trans-
mitted to an individual not carrying the same HLA allele and where
the epitope is no longer under selection pressure (138). Host HLA
may also induce selection pressure on a population level resulting
in viral adaptation within a specific genetically related population
(139). Finally, viral fitness limits the variability within some epi-
topes (140, 141). Certain HLA-alleles like HLA*B27 are considered
protective as they prime responses to highly constrained epitopes
that are less likely to mutate because of the high fitness cost (65,
142, 143).
The epitope-specific CD8 T cell receptor (TCR) repertoire may
also limit escape mutations. One study in the chimpanzee model
suggested that generation and maintenance of a repertoire with
higher diversity was associated with resolution of HCV infection
and limited the emergence of escape mutations in the targeted
epitopes (144). Another study correlated a specific mutation in an
MHC class I restricted epitope (NS31406) to the scarcity of spe-
cific TCRs that could recognize the mutant, thus exploiting this
“hole” in the T cell repertoire (67). Several studies in HIV cohorts
demonstrated an association between the ability to control HIV
replication and progressing to AIDS with the presence of specific
CD8 T cell clonotypes that possessed superior functional avidity,
as well as cross-reactivity to the different variants of the targeted
epitope (145). Additional studies examining the dynamics of the
TCR repertoire, functionality, and escape mutations during acute
and chronic HCV in relation to changes in viral quasispecies would
be of interest.
The magnitude of responding CD8 T cells also correlates with
spontaneous resolution. Studies using MHC class I tetramers
demonstrated that T cells specific for one single epitope can reach
up to 8% of CD8 T cells in spontaneous resolvers (131, 146). The
frequency of HCV-tetramer positive population was several folds
higher in the liver than in peripheral blood of chimpanzees during
acute resolving HCV with elevated expression of CD69, a marker
of T cell activation (147).
The use of MHC class I tetramers allowed direct ex vivo phe-
notypic characterization of the HCV-specific CD8 T cells. Early
expression of the IL-7 receptor alpha (CD127) on virus-specific
CD8 T cells emerged as a major predictor of spontaneous resolu-
tion while its loss was associated with viral persistence (148, 149).
CD8 memory T cell populations generated following clearance of
primary HCV infection were CD127hi and Bcl-2hi (146). This is
consistent with data from the LCMV model showing that CD127
is a marker of cells destined to become long-lived memory T cells
(150). On the other hand, HCV-specific CD8 T cells express vari-
able levels of PD-1 during acute infection suggesting that PD-1
acts more as an activation rather than an exhaustion marker (151–
153). Other exhaustion markers like the T cell immunoglobulin
and mucin domain 3 (Tim-3), cytotoxic T lymphocyte associated
antigen-4 (CTLA-4), CD160, KLRG-1, and 2B4 are differentially
expressed during acute and chronic HCV suggesting a spectrum of
exhaustion that correlated with function and persistent infection
(154, 155). The Tim-3 ligand galectin-9 (Gal-9) was upregulated in
the plasma during acute infections progressing to chronicity (155,
156) and in the liver of chronic individuals (156), thus contribut-
ing to T cell exhaustion. Blockade of PD-1, Tim-3, and CTLA-4
separately or in combination rescued HCV-specific CD8 T cells
from exhaustion suggesting that they act synergistically (157–159).
In vitro supplementation of IL-21, a mediator of CD4 T cell help,
also rescued HCV-specific T cells from Tim-3/Gal-9-mediated
apoptosis (155).
HCV-specific CD8 T cells become difficult to detect in the
peripheral blood of individual who develop chronic infection
but are readily detectable in the liver and continue to express
a highly activated and exhausted phenotype (160, 161). HCV-
specific intrahepatic CD8 T cells from chronic HCV patients
expressed TIM-3, PD-1, and 2B4, while CD8 T cells from patients
who had cleared the virus following IFN therapy (i.e., in absence
of active viral replication) and T cells specific for cytomegalovirus
lacked TIM-3 and expressed higher levels of LAG-3; these cells
also exhibited different memory phenotypes and proliferative
responses (162).
HCV-specific T cells in the peripheral blood might be slightly
impaired in their proliferative and cytokine producing capacity
when they first appear in blood suggesting a “stunned” phenotype
(163). Analysis of multiple effector functions simultaneously iden-
tified the presence of a polyfunctional population of virus-specific
CD8 T cells that correlated with spontaneous clearance of HCV
(146), similar to what was observed during control of HIV infec-
tion (164) and in the LCMV model (165). The functions analyzed
included secretion of the effector cytokines IFNγ, the T cell growth
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factor IL-2 and the degranulation marker CD107a, a surrogate
marker of cytotoxicity (146). Assays on sorted cells demonstrated
that polyfunctionality was localized within the CD127+ HCV-
tetramer reactive CD8 T cells providing further evidence to the
importance of this T cell subset in mediating viral clearance (146).
Differences in CD8 T cell functions become increasingly appar-
ent as the infection progresses and are associated with loss of helper
CD4 response, as well (discussed below). In patients who become
chronically infected T cells show progressive loss of function,
reduced polyfunctionality and diminished proliferative capacity
(146, 166). CD8 T cells detected in chronic HCV patients were
arrested in an early maturation stage, impaired in cytokine pro-
duction, cytotoxicity, and/or proliferative capacity (167–169). The
loss in function also correlates with the degree of exhaustion as
described above and were reversible in vitro upon blockade of the
PD-1, CTLA-4, and/or Tim-3 pathways (170). However, in vivo
blockade of the PD-1 pathway in chronically infected humans and
chimpanzees had limited efficacy suggesting that a threshold of
functional HCV-specific T cells is required for such immunother-
apeutic strategies to work (171, 172). Functional exhaustion could
be attributed to the persistence of the antigen, where it was shown
in the LCMV model that prolonged exposure to viral antigens is
the main cause for reduced frequency and impaired effector func-
tions of virus-specific CD8 T cells (173, 174). Confirming this
hypothesis are data demonstrating that HCV-specific CD8 T cells
detected in chronic patients where the respective cognate epitope
was mutated (i.e., no longer stimulated by the cognate epitope)
were functional and expressed lower levels of PD-1 and increased
CD127, a marker of long-lived memory cells and a predictor
of spontaneous resolution (175–177). Similarly, early therapeu-
tic intervention and sustained virologic response to IFN therapy
rescued CD127+ long-lived memory T cells (146, 176).
In summary, spontaneous resolution of acute HCV correlates
with early emergence of CD127+ HCV-specific CD8 T cells. The
response is also broad, of high frequency and polyfunctional in
nature. Several factors contribute to failure of this response in indi-
viduals who become persistently infected. First, escape mutations
in targeted epitopes facilitate viral evasion of the immune system.
Second, loss of CD4 help or a switch to an immunoregulatory
profile further compromises the antiviral capacity of virus-specific
CD8 T cells (discussed below). Third, continued viral replication
contributes to exhaustion of HCV-specific T cells through persis-
tent antigenic stimulation leading to progressive loss of function
and diminished survival of virus-specific CD8 T cells. Fourth,
exhaustion is exacerbated by increased expression of the ligands
to the inhibitory receptors like Gal-9.
CD4 T CELL RESPONSES DURING ACUTE PRIMARY HCV
The importance of CD4 T cells in clearance of primary acute HCV
was first demonstrated by the correlation between CD4 prolifera-
tive responses targeting the HCV NS proteins and viral clearance
(178, 179), whereas the loss of such responses was associated with
viral recurrence (37, 131, 180). The breadth and vigor of the CD4
response also correlated with spontaneous resolution (179, 180).
CD4 T cell responses targeting up to 14 different epitopes were
detected in individuals with acute resolving HCV (181) and some
of these epitopes were identified as promiscuous epitopes that
can be presented by multiple HLA-DR alleles (182, 183). Unlike
CD8 epitopes, escape mutations were uncommon in MHC class
II restricted CD4 T cell epitopes suggesting that this is an unlikely
mechanism of CD4 T cell failure (184, 185).
Despite the development of MHC class II tetramers and multi-
mers, direct ex vivo detection and characterization of HCV-specific
CD4 T cells has been limited due to the low frequency of tetramer
reactive T cells, very often requiring enrichment. In addition, the
restricted number of epitopes and tetramers that are available
limited such analysis. Direct ex vivo studies have demonstrated
that HCV-specific CD4 T cells are detectable by tetramers mostly
during the acute phase. The frequency declines and they remain
detectable in humans who resolve the infection during the memory
phase but require enrichment where they were shown to express
markers of central memory T cells (CCR7+CD45RA−CD27+)
(186, 187). Nevertheless, HCV-specific CD4 T cells were detectable
directly ex vivo by MHC class II tetramers in one chimpanzee at
7 years post resolution of acute primary HCV (152). The use of
tetramers also revealed that broad virus-specific CD4 T cells were
present early in most individuals acutely infected with HCV irre-
spective of the outcome, but rapidly lost the proliferative capacity
and cytokine production, specifically IL2, and disappeared from
the periphery with the establishment of chronic infection (188,
189). This challenged the prevailing hypothesis that HCV persis-
tence is the result of a failure to prime virus-specific CD4 T cells
and suggested that it is rather T cell exhaustion and the failure to
sustain such CD4 T cell responses that leads to chronicity. Indeed,
in vitro blockade of the PD-1, IL-10, and TGF-β pathways rescued
the proliferative and cytokine producing capacity of CD4 T cells
from individuals with chronic HCV (190).
The importance of CD4 T cell help in maintaining a func-
tional CD8 T cell response during HCV infection was clearly
demonstrated by CD4 depletion studies in chimpanzees, where the
frequency of virus-specific CD8 T cells and their cytokine produc-
ing capacity gradually declined resulting in accumulation of escape
mutations in the targeted CD8 epitopes (191). So how do HCV-
specific T cells provide help for CD8 T cells? Our group recently
demonstrated that expansion of CD161hiCCR6+CD26+CD4+
Th17 T cells correlated with spontaneous resolution of HCV.
These cells produced large amounts of IL-17A and IL-21 and
this correlated with the increased plasma concentration of these
two cytokines and spontaneous resolution of HCV (155). Specifi-
cally, increased plasma levels of IL-21 during the late acute phase
correlated with the frequency of virus-specific CD8 T cells and
rescued them from Tim-3/Gal-9-mediated apoptosis (155). This
underscored the role of IL-21 as a major helper cytokine similar
to previous observations on the LCMV model and HIV (192).
Other sources of IL-21 like NK cells and follicular helper T cells
(Tfh) remain unstudied and may play an active role in mediating
CD4 help.
Virus-specific Th17 and regulatory T cells (Tregs) were detected
during acute and chronic HCV (193–195) and Th17-like CD4 T
cells were enriched in the livers of individuals with chronic HCV
(196). The preferential expansion of Tregs with viral persistence
may represent another level of inhibition of HCV-specific CD4
and CD8 T cells. CD39+CTLA4+ Tregs were expanded during
acute HCV infections progressing to chronicity with a shift in the
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Th17/Treg balance (155). Such Tregs can be a source of Gal-9 fur-
ther contributing to the inhibition/exhaustion of CD4 and CD8 T
cells expressing Tim-3 (155). Tregs are also expanded in chronic
HCV but it is not yet clear if expansion of Tregs is a cause or an
effect of HCV persistence as a feedback mechanism to limit virus
induced immunopathology and inflammation. A recent report
suggested that subinfectious exposures to HCV in the chimpanzee
model may predispose to the development of Tregs that can later
suppress HCV-specific responses upon subsequent infection (197)
suggesting that elevated Tregs can be a cause of persistence. Finally,
the flexibility and reversible nature among the different T-helper
subsets is a domain of intense research (198) and whether HCV-
specific CD4 T cells are endowed with such plasticity and the
pathways involved remain to be seen.
In summary, broad HCV-specific CD4 T cell responses are
primed during most acute HCV infections. However, contraction
of this CD4 T cell population and its failure in sustaining a robust
CD8 T cell effector response is a hallmark of HCV persistence.
Early induction of IL-21 producing Th17 cells is critical to mediate
help and limit exhaustion of virus-specific CD8 T cells. However,
CD4 T cell exhaustion, leads to sequential loss of IL-2 produc-
tion, proliferative capacity, and IFNγ production in addition to an
imbalance in the Th17/Treg ratio. Tregs may contribute to exhaus-
tion and inhibition of CD4 and CD8 T cells through production
of the Tim-3 ligand Gal-9 and the regulatory cytokines IL-10 and
TGF-β.
HUMORAL RESPONSES DURING ACUTE PRIMARY HCV
Although, HCV RNA reaches high serum titers by week 2 post
infection, anti-HCV antibody response (seroconversion) is usu-
ally not detected before week 8 (199, 200). Early studies showed
that antibodies (Abs) targeting the HVR-1 region of the E2 gly-
coprotein of HCV are neutralizing in vitro and in vivo (201, 202),
but select for mutations in the envelope region (203). Chimpanzee
studies showed that generation of Ab responses was not necessarily
associated with viral clearance (204, 205). In humans,Ab responses
were delayed, were of low titers and declined rapidly in individuals
who cleared HCV spontaneously (206–208). One study showed
that nAbs appeared in patients after HCV has already established
chronic infection and were unable to clear the virus and selected
for escape mutants (209). However, another study showed that
early induction of nAbs was associated with spontaneous reso-
lution of HCV primary infection (210). Broadly nAbs that could
protect against heterologous HCV infection were recently reported
(211, 212). Similar broadly nAbs confer protection against most
pathogens, yet, they did not necessarily correlate with the control
of infection or protection against superinfection in some chronic
viral infections like HIV (213).
One of the major limitations for understanding humoral
immunity against HCV is the lack of proper tools to measure
precisely the levels of nAbs. The current method measures neu-
tralization of HCVpp or infectious virions carrying HCV E1–E2
envelope glycoproteins corresponding to a limited number of
HCV genotypes reference sequences, and thus do not necessarily
represent the autologous E1/E2 sequences circulating in the patient
(214, 215). An HCVpp library comprised of 19 genetically-distinct
sequences that represent the natural variability of genotype 1
E1/E2 was recently used to demonstrate the evolution of the HVR-
1 sequences in response to nAbs (216). A recent study using this
HCVpp library demonstrated that resolution of HCV infection
was associated with a broad nAb response generated early during
the infection (217).
Another antiviral role for anti-HCV Abs could be through
induction of antibody-dependent cellular cytotoxicity (ADCC).
ADCC is a mechanism whereby the variable region of Abs binds
to infected cells while the constant region (Fc) is recognized by Fc
receptors expressed by various innate immune cells including NK
cells. Binding to the FcγR3a (CD16) triggers cytokine production
and degranulation of NK cells, resulting in lysis of the targeted cell.
Several studies suggest that ADCC plays a role in controlling viral
replication during HIV infection (218, 219) and may have con-
tributed to the success of the HIV RV144 vaccine trial performed
in Thailand (220). So far, only one study has demonstrated the
presence of ADCC-inducing antibodies specific for the E2 envelop
protein in several HCV patients during acute and chronic HCV
infection, as well as after spontaneous clearance (221). Further
studies will be required to confirm these results and determine if
ADCC-inducing antibodies play a role in the spontaneous clear-
ance of HCV infection and in the protection against HCV infection
and reinfection.
Some major challenges exist for generating protective humoral
immunity against HCV. First, the envelope proteins are not highly
immunogenic, causing the Ab response to be slow and weak during
primary infection (216). Second, Abs mostly target the HVR of E2,
a region with high mutation rates, which facilitates the selection of
viral sequences that are highly resistant to Ab neutralization (222).
This selection was shown to take place as the cellular immunity
collapsed and the infection progressed to chronicity (223). Third,
the epitopes targeted by nAbs are shielded by heavy glycosyla-
tion and complexation with host lipoproteins, which limits their
efficacy in vivo (224).
In summary, recent data suggest that nAbs are induced earlier
than what was previously thought and may play an active role in
spontaneous resolution but these results remain inconclusive and
further investigation using autologous E1/E2 sequences is required
to understand this role. The recent elucidation of the crystal struc-
tures of E2 (225) and E2 bound to the broadly nAb AR3C (226), as
well as structural mutational studies should provide better insights
into how E1/E2 interact with their receptors and nAbs. In addi-
tion, the role of CD4 T cells, in particular Tfh cells, in providing
help for antibody production by B cells remains undefined.
SUMMARY OF ACUTE PHASE IMMUNE RESPONSES AND
MECHANISMS OF IMMUNE EVASION
Hepatitis C virus infection of hepatocytes activates innate immune
sensing mechanisms like TLRs, RIG-I, and PKR that activate sig-
naling cascades resulting in production of type I and type III IFNs
and induction of several antiviral ISGs in infected hepatocytes.
HCV can also be transferred to DCs or Kupffer cells via exosomes
leading to activation of innate pathways and additional secretion
of IFNs. Intrahepatic NK cells are activated by IFNs and recognize
and kill HCV-infected hepatocytes generating apoptotic bodies
containing HCV antigens. These apoptotic bodies are taken up
by APCs like Kupffer cells and DCs that process and present HCV
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antigens as peptides bound to MHC class I and II and prime HCV-
specific CD8 and CD4 responses, respectively. Infected hepatocytes
also present processed HCV antigens in the context of MHC class
I and prime virus-specific CD8 T cells that contribute to killing
and generation of additional apoptotic bodies containing viral
antigens. The transfer of HCV antigens from the liver to drain-
ing lymph nodes via migratory DCs is thought to be critical for
priming of efficient immune responses. Several populations of
HCV-specific CD4 helper T cells are primed including Th1 cells
that provide help for CD8-mediated killing of infected hepatocytes
via production of IFNγ and TNFα, Th17 cells that produce IL-21
that limits exhaustion of HCV-specific CD8 T cells and rescues
them from apoptosis and Th2 cells that provide help for antibody
producing B cells and generation of nAbs via IL-4 and IL-6. The
role of Tfh cells and their support for development of nAbs remain
undefined during acute HCV, as well as the potential contribution
of ADCC to viral control. Similarly, cross-talk between NK cells
and DCs and how this interaction influences priming of virus-
specific T cells and regulates their function are unknown. HCV
can evade innate immunity by interfering with the IFN-signaling
pathway, inhibiting NK cells’ functions (even transiently), escape
mutations of targeted CD8 T cell epitopes, or exhaustion of virus-
specific CD4 and CD8 T cells through upregulation of exhaustion
molecules like PD-1, Tim-3, CTLA-4, and others. Tregs are also
induced and they can dampen HCV-specific responses directly
through secretion of the immunoregulatory cytokines IL-10 and
TGF-βor production of Gal-9 that can induce apoptosis of Tim-3+
virus-specific Th1, Th17, and CD8 T cells (Figure 2).
PROTECTIVE IMMUNITY AGAINST HCV
HCV-specific memory CD4 and CD8 T cells were detectable in the
peripheral blood of humans who have spontaneously resolved pri-
mary acute HCV for up to 20 years following viral clearance while
antibody responses waned (227). Similarly, memory CD4 and CD8
T cells were detectable in the peripheral blood and liver of HCV-
resolved chimpanzees at 7 years following resolution of primary
infection (147). Virus-specific CD4 and CD8 T cells were also
detectable in individuals with potential occupational, household
contact, or high risk behavior like injection drug use, in absence
of detectable antibody responses or history of infection suggest-
ing subclinical exposure, and priming of HCV-specific memory T
cells (228–231).
The frequency of HCV-specific memory T cells was stable for
several years after the resolution of primary infection in chim-
panzees (147). Rechallenge studies demonstrated no sterilizing
immunity but were characterized by a shorter duration of viremia
and lower viral loads and were associated with protection from
virus persistence in most (147, 232–235), but not all studies (236).
Expansion of HCV-specific memory CD4 and CD8 T cells in
peripheral blood and the liver was associated with rapid control of
HCV infection upon rechallenge. IFNγ producing CD4 and CD8
T cells were detected at a higher frequency and much earlier during
secondary infection as compared to primary infection in the same
chimpanzees (147, 191, 232–235). The hierarchy of CD4 helper T
cell epitopes was preserved during secondary infection years later
(182). Control of viral replication in animals challenged with HCV
following experimental vaccination was associated with priming
of CD127+ PD-1lo CD8+ T cells that persisted at high levels for
prolonged periods and were bifunctional, producing both IFNγ
and TNFα (237). Another study demonstrated that clearance of
HCV reinfection upon heterologous rechallenge involved the acti-
vation of both innate and adaptive immune responses. Higher
intrahepatic gene expression of CD56, CD8, type I and II IFN, and
ISGs were observed in one out of two chimpanzees who were able
to clear the rechallenge virus (238). This response correlated with
expansion of HCV-specific CD4 and CD8 T cells in the peripheral
blood in absence of nAbs (238).
The protective role of memory CD4 and CD8 T cells was con-
firmed using antibody-mediated depletion. CD4 T cell depletion
was associated with low level viremia. Although memory CD8
T cells initially provided some control for viral replication, they
rapidly waned in absence of CD4 T cell help leading to accumula-
tion of escape mutations in targeted epitopes and viral persistence
after more than 1 year of follow-up (191). In contrast, memory
CD8 T cell depletion led to a significant delay in control of viremia,
and this control coincided with the recovery of HCV-specific T
cells in blood and liver (147). Altogether, these data demonstrate
a protective role for memory T cells upon reexposure to HCV but
the role of nAbs was not sufficiently analyzed due to lack of the
proper tools and the generally weak anti-HCV antibody response
induced in chimpanzees.
As described above, HCV-specific memory CD4 and CD8 T
were detectable 20 years post-clearance of the virus, whereas anti-
bodies were barely detectable (227). Phenotypic characterization
of HCV-specific CD4 T cells in spontaneously resolved cases
showed they were CCR7+, CD45RA−, and CD27+, characteristic
of central memory T cells (186). Spontaneous resolution from a
primary HCV infection was associated with the generation of poly-
functional HCV-specific memory population expressing CD127hi
Bcl-2hi profile (146, 148, 149) consistent with a profile of long-lived
memory CD8 T cells (150). It is not clear how HCV-specific mem-
ory CD4 and CD8 T cells are maintained for prolonged periods.
Apart from their intrinsic long-lived properties and transcriptional
profile, memory T cells can be maintained through homeostatic
proliferation in response to the γ-chain cytokines IL-7, IL-15, and
IL-21 (239, 240). They may also be maintained through periodic
restimulation with cross-reactive viral or self-antigens. Finally, it
is possible that minor quantities of HCV RNA are maintained for
a prolonged period following viral clearance and contribute to
periodic restimulation of such memory T cells (241, 242).
The protective role of HCV-specific immunological memory
is difficult to address in humans. Nevertheless, epidemiological
studies demonstrated that high risk IDUs who have spontaneously
resolved one HCV infection were less likely to be reinfected than
HCV-naïve individuals despite repeated high risk exposures (243–
246), but the reported rate of incidence of reinfections was variable
because of the different HCV RNA testing interval where rein-
fections of shorter duration or accelerated viral clearance may
have been missed (247). Other factors include differences in the
characteristics of individual subjects, as age, ethnicity, and risk
behaviors (247). Nevertheless, the rate of spontaneous clearance
of reinfection was higher than that for primary infection (243, 245,
248). This provided preliminary evidence of protective immunity
against HCV. Osburn et al. monitored a group of high risk IDUs at
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FIGURE 2 | Summary of innate and adaptive immunity during primary
HCV infection. (1) HCV entry and replication inside hepatocytes induces the
production type I and type III IFNs that are also secreted by pDCs and
create an antiviral state in infected hepatocytes and neighboring cells and
stimulate NK cells that kill infected hepatocytes. (2) Liver resident and
migratory APCs (Kupffer cells and DCs) uptake apoptotic bodies from
destroyed HCV-infected hepatocytes and present HCV-derived epitopes to
both CD4 and CD8 T cells in the context of MHC class II and MHC class I,
respectively. (3) The cross-talk between DCs and NKs regulates the function
of both cells enhancing antigen presentation and priming, as well as
NK-mediated killing. (4) CD4 helper T cells support responses of CD8 T cells
and B cells through production of Th1 and Th2 cytokine, respectively. (5)
Whether Abs produced from B cells during primary infection have an
essential role in viral clearance by directly neutralizing the virus or by
mediating ADCC is not fully understood, and the role of Tfh cells in this
process is still unknown. (6) CD8 T cells eliminate HCV-infected cells
through direct cytotoxic mechanisms (cytolytic granules, as perforin and
granzyme) or non-cytolytic mechanisms through secretion of the antiviral
cytokines IFNγ and TNFα. (7) CD8 T cell functions are sustained and
enhanced by IL-21 mainly produced by Th17 cells. IL-21 is also essential to
rescue virus-specific T cells from exhaustion caused by persistent exposure
to HCV antigens. Reduced IL-21 production or Th17 cell numbers results in
an increased exhaustion status and expression of exhaustion markers like
PD-1, Tim-3, CTLA-4, and others. (8) Regulatory T cells might be a cause in
the failure of the primary immune response by secreting the regulatory
cytokines TGFβ, IL-10, or secretion of Gal-9 that enhances apoptosis of
Tim-3+ CD4 and CD8 T cells. ADCC, antibody-dependent cellular
cytotoxicity; APC, antigen-presenting cell; CTLA-4, cytotoxic T lymphocyte
antigen-4; DC, dendritic cell; FcR, receptor for the constant fragment of the
antibody; Gal-9, galactin-9; Gz, granzyme; HCV, hepatitis C virus; IFN,
interferon; IL, interleukin; NK, natural killer; PD-1, Programed death-1; pDC,
plasmacytoid DC; Tfh, T follicular helper cells; TGF, transforming growth
factor; Th17, T-helper 17 cell; Tim-3, T cell immunoglobulin and mucin domain
3; TNF, tumor necrosis factor; Treg, regulatory T cell.
monthly intervals and observed a rate of reinfection at almost 50%
(11/22). Spontaneous clearance of reinfection was associated with
broadened T cell responses and generation of cross-reactive Ab
responses (248). However, phenotypic and polyfunctional char-
acterization of HCV-specific memory CD4 and CD8 T cells was
not performed. In this study, 10/11 subjects examined resolved
the second infection, thus a control group of unprotected patients
that would enable the definition of the exact correlates of protec-
tion was lacking. Preliminary work from our group suggests that
protection from HCV persistence upon reinfection is variable and
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associated with expansion of HCV-specific memory CD8 T cells
that are polyfunctional in nature with expansion of a CD127lo
population consistent with effector memory T cells (249).
Early treatment of HCV could rescue long-lived HCV-specific
memory CD4 and CD8 T cells (146, 176, 189) but the protective
role of natural T cell memory generated after viral clearance versus
treatment induced memory generated after therapeutic-mediated
clearance remains to be evaluated. An equally protective memory
immune response would argue in favor of early treatment of high
risk individuals as this will provide them with long-term protec-
tion if they are reexposed. Comparison of the capacity of the new
DAAs and/or IFN free regimens to rescue such protective memory
responses should also be evaluated.
In summary, long-lived T cell memory responses are generated
following spontaneous HCV clearance and data from chimpanzees
and limited human studies suggest that they can provide some pro-
tection. However, the signatures of a protective immune response
upon reexposure are far less defined, especially in terms of the
phenotype and functionality of HCV-specific protective mem-
ory immune responses. We propose a model inferred from our
current knowledge of protective immunity during acute primary
HCV infection (Figure 3). We hypothesize that protection upon
reexposure is associated with the maintenance of higher frequency,
breadth, and polyfunctionality of HCV-specific memory CD4 and
CD8 T cells. Such long-lived memory T cells are likely main-
tained through homeostatic proliferation in response to γ-chain
cytokines. Upon reexposure, these memory T cells expand rapidly
and eliminate the infecting virus. Similar to murine models of
viral infections, repeated exposure will select for the virus-specific
memory T cells with the highest proliferative capacity and func-
tional avidity (250). It is likely that such long-lived memory T cells
will acquire a genomic signature that will facilitate their capac-
ity to expand rapidly and effectively upon reexposure. Individuals
who cannot maintain such long-lived, broad, and polyfunctional
memory T cells because of reduced homeostatic cytokine or pro-
liferation or predisposition to generation of Tregs and increased
T cell exhaustion are less likely to be protected upon reexpo-
sure. Host genetics, nAbs and homology between the infecting
viral strains during primary and secondary infection can tip
the balance toward viral clearance or persistence of the second
infection.
Protective immunity in the context of real life exposure remains
the most understudied area of HCV due to the limited number
of organized high risk cohorts suitable for such studies and the
need for follow-up at close intervals to detect multiple infection
episodes (247). Concerted efforts to study such response on a
large scale in matched cohorts with different ethnic backgrounds
are underway and should yield important knowledge in the future
(251, 252). In addition, the organization and characterization of
such cohorts provides the perfect setup to evaluate vaccine can-
didates. Use of novel genomic and proteomic tools should yield
better insights about the pathways involved in protective immu-
nity. Comparative analysis of virus-specific cellular and humoral
responses in relation to variations in the infecting viral strain
is essential to understand the interplay between the virus and
immune system and cross-protective immunity.
IMPLICATIONS FOR VACCINE DEVELOPMENT
The need of a prophylactic HCV vaccine to prevent viral transmis-
sion remains an urgent need to reduce the future disease burden
worldwide (11). The plethora of data suggesting that cellular
immunity is the major arm mediating spontaneous clearance dur-
ing primary HCV infection led to the assumption that it should be
the target for vaccine development. Nevertheless, the recent data
on the role of nAbs in resolution of primary infection suggest a
possible contribution of humoral immunity in both primary HCV
clearance and prophylaxis.
There are two challenges facing the development of HCV vac-
cines. First, the genetic diversity of HCV sequences and its high
rate of mutability. Second, the ability of HCV proteins to dis-
rupt and evade the different arms of the immune system. This
necessitates the design of an effective vaccine that generates mem-
ory immune cells capable of mounting a prompt recall response
upon reexposure to diverse HCV strains in a fashion that out-
paces the virus and prohibits it from crippling the immune
system.
Three major approaches have been adopted for vaccine design
against HCV. The traditional approach uses recombinant envelope
proteins to induce nAbs. It has gained more potential recently
with the discovery of broadly nAbs. Vaccination with recombi-
nant E1/E2 proteins was shown to induce cross-reactive nAbs that
might contribute to protective immunity upon exposure to HCV
(253–255). The second approach uses virus-like particles (VLPs)
that express HCV structural proteins to induce both humoral and
cellular immunity, but it failed to induce humoral responses when
tested in chimpanzees. Furthermore, upon homologous rechal-
lenge 2/4 vaccinated chimpanzees demonstrated sporadic very low
levels of viremia during 1 year of follow-up (256). The third and
most promising approach is designing an HCV vaccine that would
induce a potent T cell immune response. Replication-defective
recombinant viral vectors [e.g., adenovirus (Ad), vaccinia virus
(VV), modified vaccinia Ankara (MVA)] were used to deliver HCV
antigens to prime T cell responses. Another promising vector that
was successful in the simian immunodeficiency virus (SIV) model,
but has not yet been tested in HCV is cytomegalovirus (257). HCV
proteins could also be delivered using DNA vaccines, where recom-
binant plasmids expressing various proteins could be injected into
the host [reviewed in Ref. (11)].
A combination of viral vector prime and DNA or recombi-
nant protein boost is preferred to prevent neutralization of the
subsequent boosts by vector-specific antibodies that could have
been generated during priming. Two candidate vaccines using
this strategy showed promising preliminary results and are at an
advanced stage of development. The first vaccine uses heterolo-
gous prime/boost regimens with chimpanzee adenovirus Ad3Ch3
and a rare strain of human adenovirus (Ad6) expressing the entire
NS region of genotype 1b BK strain (NS3-5B). This vaccine was
tested in a phase I clinical trial in humans (ClinicalTrials.gov
NCT01436357). Both vectors primed broad CD4 and CD8 T cell
responses that were capable of responding to heterologous strains
of HCV genotypes 1a and 3a. Polyfunctional HCV-specific T cells
(IL-2+ IFNγ+ TNFα+) could be sustained for at least a year
after boosting with the heterologous vector (258). This vaccine
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FIGURE 3 | Hypothetical model for protective and non-protective
immunity upon HCV reinfection. Individuals who spontaneously clear
primary HCV infection develop long-lived virus-specific memory CD4 and
CD8 T cells. Such memory T cell populations are maintained by the action of
homeostatic cytokines like IL-7, IL-15, and IL-21. Upon HCV reinfection,
some individuals will be protected against viral persistence while others will
be unprotected. (A)The protected individuals will be able to spontaneously
clear the second infection with a shorter period of viremia and reduced peak
viremia. Viral clearance will be accompanied by an accelerated memory T
cell recall response detectable in both liver and blood. The exact
characteristics of a protective response are yet to be defined in terms of
breadth and quality. (B) In unprotected individuals, reinfection will be
associated with a weak or late recall response and incomplete T
cell-mediated control of viremia. The underlying causes of failure to resolve
the reinfection despite the ability to spontaneously resolve a prior infection
maybe low levels of homeostatic cytokines affecting the maintenance of
memory T populations, reduced breadth, or quality of the recall response
upon reinfection and increased frequency of Tregs leading to dampening of
the immune response, viral persistence, and rapid exhaustion of
HCV-specific T cells. Neutralizing antibodies, host genetics, and homology
between the infecting viral sequences at different episodes may play a role
in protection upon reinfection.
is currently in a phase II trial in high risk IDUs. The second vac-
cine uses a regimen of priming with Ad6 encoding NS3-5B of
genotype 1b BK strain and boosting with NS3-5B-encoding plas-
mid DNA. A study in chimpanzees that received this vaccine then
challenged with HCV demonstrated that control upon HCV chal-
lenge following vaccination was associated with CD127+ PD-1lo
CD8 T cells that persisted at high levels for prolonged period and
were bifunctional (IFNγ+ TNFα+). Nevertheless, three out of five
chimpanzees were not protected suggesting that a more efficient
immune response may be required (237, 259).
Correlates of protective immunity against HCV need to be
clearly defined so that they could be monitored following vac-
cination to predict the degree of protection that may be con-
ferred. This should involve characterization of the genomic and
proteomic pathways involved and identification of biomarkers
that can be used as benchmarks to monitor vaccine success in
a non-invasive way. Strategies targeting both cellular and humoral
immunity are likely to be more successful (260). The use of
immune modulators like PD-1 blockers, TLR agonists, or mod-
ulators of biological pathways like transcription factors involved
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in memory T cell generation may be useful as vaccine adjuvants
to enhance immunogenicity and favor the development of the
desirable immune response (250).
FUTURE RESEARCH DIRECTIONS
There is a general misconception that this is the end of HCV and
that the new treatments will completely eliminate HCV within the
next few years. Unfortunately, this is highly unlikely since the new
DAAs remain expensive and are associated with a fair number of
side effects. Moreover, their use in special populations like indi-
viduals with advanced liver disease or HIV coinfection remains
experimental and limited at this point. Most importantly, many of
the individuals infected with HCV have not been tested and con-
tinue to infect others. Future research should focus on the many
shades of gray that still cloud our understanding of what consti-
tutes a long-term protective immune response and the interaction
between the virus and the host. This requires the use of orga-
nized and well characterized cohorts and standardized methods
to evaluate immunity on a large scale with sufficient statistical
power. Areas of interest involve better understanding of the role of
genetic predictors of HCV outcome like IL28B and IFNL4 in viral
clearance and long-term protection; understanding the nature of
CD4 T cell help for both CD8 T cells and antibody producing B
cells; elucidation of the role of neutralizing and non-nAbs during
primary and secondary HCV infections; development of better
small animal models for preclinical testing of vaccines and the
use of novel genomics and proteomics tools to identify implicated
pathways and non-invasive markers of efficient immune response.
Collaboration with other fields, including research on vaccines for
other viruses like yellow fever virus and HIV, as well as work with
more physiologically relevant in vitro models like primary hepa-
tocytes should provide a clearer image of the protective immunity
against HCV and better success for ongoing and future vaccine
development strategies.
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